MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 66 filers reported holding MEREO BIOPHARMA GROUP PLC in Q2 2022. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,241,642 | -6.8% | 962,513 | -4.6% | 0.39% | +6.0% |
| Q2 2023 | $1,331,897 | +71.8% | 1,009,013 | -8.0% | 0.36% | +56.9% |
| Q1 2023 | $775,125 | -5.7% | 1,096,513 | 0.0% | 0.23% | 0.0% |
| Q4 2022 | $822,385 | -12.9% | 1,096,513 | 0.0% | 0.23% | -8.7% |
| Q3 2022 | $944,000 | -23.1% | 1,096,513 | 0.0% | 0.25% | -24.2% |
| Q2 2022 | $1,228,000 | -9.9% | 1,096,513 | -9.9% | 0.34% | -5.6% |
| Q1 2022 | $1,363,000 | -24.4% | 1,216,613 | +8.0% | 0.36% | -21.6% |
| Q4 2021 | $1,803,000 | -33.9% | 1,126,613 | 0.0% | 0.45% | -37.3% |
| Q3 2021 | $2,726,000 | -23.7% | 1,126,613 | 0.0% | 0.72% | -3.2% |
| Q2 2021 | $3,571,000 | -15.2% | 1,126,613 | -9.8% | 0.75% | -25.2% |
| Q1 2021 | $4,211,000 | +76.0% | 1,249,648 | +87.0% | 1.00% | +40.3% |
| Q4 2020 | $2,392,000 | +358.2% | 668,148 | +235.0% | 0.71% | +318.8% |
| Q3 2020 | $522,000 | +122.1% | 199,425 | +159.7% | 0.17% | +150.0% |
| Q2 2020 | $235,000 | – | 76,800 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 6,220,938 | $16,299,000 | 0.94% |
| Boxer Capital, LLC | 4,029,649 | $10,558,000 | 0.36% |
| DAFNA Capital Management LLC | 199,425 | $522,000 | 0.17% |
| J. Goldman & Co LP | 443,517 | $1,162,000 | 0.08% |
| Ikarian Capital, LLC | 1,196,308 | $688,000 | 0.05% |
| HHLR ADVISORS, LTD. | 1,598,185 | $4,187,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 133,634 | $350,000 | 0.02% |
| F3Logic, LLC | 255 | $668,000 | 0.02% |
| Schonfeld Strategic Advisors LLC | 343,195 | $899,000 | 0.02% |
| CSS LLC/IL | 54,773 | $144,000 | 0.01% |